Argenx’s partner Bird Rock Bio demonstrates potential for gerilimzumab, a novel SIMPLE antibody™ against IL-6 to treat rheumatoid arthritis

Date: 16/03/2016

16 March 2016 – Breda, The Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX) today reported that its partner Bird Rock Bio (formerly RuiYi) has announced that gerilimzumab, a novel SIMPLE Antibody™ neutralizing the IL-6 cytokine, has demonstrated safety and pharmacokinetics that support low, infrequent dosing and the potential for favorable pricing.

Bird Rock Bio initiated two clinical trials in healthy adult volunteers focused on the pharmacokinetics of gGerilimzumab in single and multiple ascending dose studies where the compound was administered by subcutaneous injection. A total of 50 subjects were included in both studies, which assessed the safety and tolerability of gerilimzumab compared with placebo. Gerilimzumab was well tolerated and no serious adverse events were reported. Positive results from this study support advancing the compound into trials in patients with autoimmune disorders. Bird Rock Bio plans to complete submission for a pivotal trial for rheumatoid arthritis by the first half of 2016.

Tim Van Hauwermeiren, CEO at argenx commented: “The favorable outcomes of the two studies for gerilimzumab represent an exciting step forward for this exceptional antibody. Gerilimzumab was originally discovered using our SIMPLE Antibody™ platform and was further differentiated with our proprietary NHance® technology in order to prolong the circulation time and improve tissue distribution of antibodies. We are very pleased with how rapidly Bird Rock Bio has successfully progressed gerilimzumab.”